Aflac Q4 revenue beats analyst expectations on Japan growth

Aflac

04/02/2026 21:14

Overview

Supplemental health insurer's Q4 revenue beats analyst expectations

Adjusted EPS for Q4 missed analyst estimates

Company announced a 5.2% increase in first quarter dividend

Outlook

Company plans to promote new products in Japan in 2026

Result Drivers

JAPAN SALES GROWTH - Aflac Japan's sales increased 15.7% in Q4, driven by strong demand for the new cancer insurance product, Miraito

U.S. PREMIUM INCREASE - Aflac U.S. net earned premiums rose 4.0% in Q4, reflecting improved sales and strong persistency

INVESTMENT INCOME DECLINE - Adjusted net investment income fell due to lower floating rate income and variable net investment income

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$4.90 bln
$4.31 bln (5 Analysts)
Q4 Adjusted EPS
Miss
$1.57
$1.69 (13 Analysts)
Q4 EPS
$2.64
Q4 Adjusted Net Income
Miss
$818 mln
$887.88 mln (8 Analysts)
Q4 Net Income
$1.40 bln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 8 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the life & health insurance peer group is "buy."

Wall Street's median 12-month price target for Aflac Inc is $111.00, about 0.9% below its February 3 closing price of $112.04

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nPn4YqXx9a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)